Full HTML

Gastric Plexiform Fibromyxoma: A Narrative Review of a Rare Mesenchymal Tumor

Sajad Ahmad Salati¹, Ajaz Ahmad Rather²

Author Affiliation

1 Professor, Department of Surgery, College of Medicine, Qassim University, Buraydah, Saudi Arabia
2 Professor, Department of Surgery, SKIMS Medical College, Srinagar, Jammu and Kashmir, India

Abstract

Gastric plexiform fibromyxoma (GPF) is a rare mesenchymal tumor that primarily affects the stomach, and to date, only about 170 cases have been reported. It is benign in nature with a favorable long-term prognosis. GPF mimics many disease entities, including the malignant ones, and the proper diagnosis differentiation requires a battery of investigations, including imaging, histopathology, immunochemistry, and molecular genetics studies. Management is generally surgical. This article is drafted to revisit various aspects of GPF to enhance the level of awareness in healthcare providers.

DOI: 10.63475/yjm.v4i3.0216

Keywords: Benign gastric tumor, gastric plexiform fibromyxoma, gastrointestinal stromal tumor, plexiform angiomyxoid myofibroblastic tumor, immunohistochemistry

Pages: 507-513

View: 4

Download: 5

DOI URL: https://doi.org/10.63475/yjm.v4i3.0216

Publish Date: 31-12-2025

Full Text

INTRODUCTION

Gastric plexiform fibromyxoma (GPF) is a rare mesenchymal tumor that primarily affects the stomach. [1,2] The pathogenesis and molecular alterations of GPF are mostly unknown because of its rarity. [3] Following its initial description in 2007, about 170 case reports have been reported in peer-reviewed English-language literature. The condition is benign, but to establish a diagnosis, it must be distinguished from the many other malignant breast lesions that closely mimic it due to their molecular, histological, and radiological characteristics. [4–6] Given the extreme rarity of these tumors, awareness about this disease is limited, and hence, this article has been drafted to contribute to the existing literature and review the pathogenesis, clinical presentation, investigations, treatment, and outcomes.